martes, 17 de noviembre de 2026

Oncology News: LUGPA 2026 - Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC (+...)

Oncology News LUGPA 2026 Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC Despite a recent FDA approval, urologic oncologists are waiting for more data before embracing durvalumab add-on for patients with high-risk non-muscle invasive bladder cancer. Medscape Medical News, November 17, 2026 https://www.medscape.com/index/list_13474_0

No hay comentarios:

Publicar un comentario